Trial Profile
A phase III pivotal,multinational, multicenter pivotal trial evaluating TNP-2092 for prosthetic joint infections
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2020
Price :
$35
*
At a glance
- Drugs TNP 2092 (Primary)
- Indications Bacterial infections
- Focus Registrational; Therapeutic Use
- 28 Jan 2020 According to a TenNor Therapeutics media release, this phase III study will commence soon.
- 28 Jan 2020 According to a TenNor Therapeutics media release, the company is planning to submit the New Drug Applications in both USA and China.
- 04 Oct 2016 New trial record